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Fibroids are very common in Afro-Caribbean women. They can cause severe complications. The treatment modalities are not
without risk and should be weighed against the complications of the ﬁbroids.
1.Introduction
Leiomyomata uteri (uterine ﬁbroids) are benign tumours of
the smooth muscle of the uterus. These tumours have prev-
alence ranging from 20 to 50% of women depending on
the age, ethnicity, parity, and methods use to assess their
presence. In one series, they were said to be present in 77%
of postmortem specimens where detailed examination of the
uterus was done looking for theses ﬁbroids. In that series,
over 50% of the women were asymptomatic [1].
Uterine ﬁbroids grow under the inﬂuence of the hor-
mone oestrogen and are most often seen after the menarche,
and tend to shrink after the menopause. Typically the patient
is nulliparous or of low parity and they are more commonly
seen in women of African ancestry.
Common complications of uterine ﬁbroids include men-
orrhagia with symptoms of anaemia, dysmenorrhoea, pres-
sure symptoms, abdominal distension, and infertility. Infer-
tility appears to be an incidental ﬁnding rather than a
consequence of the ﬁbroid, except in cases of submucosal
ﬁbroids [2, 3]. Other complications include degeneration,
torsion, prolapse of a submucous ﬁbroid, ureteric obstruc-
tion, venous thromboembolism, intestinal obstruction, and
malignant transformation.
2. Menorrhagia
Menorrhagia is deﬁned as regular, cyclic menstrual ﬂow with
excessive volume and durations. Clinically, menorrhagia is
deﬁned as total blood loss exceeding 80mL per cycle or
menses lasting longer than 7 days [4]. In practice, measuring
menstrual blood loss is diﬃcult. Thus, the diagnosis is
usually based upon the patient’s history. These patients will
complain of ﬂooding, overﬂow, and passage of large clots. In
many cases women will notice that they have an increased
need for sanitary napkins compared to those obtained in the
past.
Menorrhagia must be distinguished clinically from other
common gynecologic diagnoses. These include metrorrhagia
(ﬂow at irregular intervals), metromenorrhagia (frequent,
excessive ﬂow), and polymenorrhea (bleeding at intervals
<21d).
The mechanism by which ﬁbroids cause menorrhagia is
not well understood. The blood supply to the ﬁbroid is dif-
ferent compared to the surrounding endometrium and is
thought to function independently. This blood supply is
greater than the endometrial supply and may have impeded
venous return, causing pooling in the areas of the ﬁbroid.
Heavypoolingisthoughttoweakentheendometriuminthat
area, and breakthrough bleeding ensues.
Fibroids located withinthe uterine wallmay inhibit mus-
cle contracture, thereby preventing normal uterine attempts
at haemostasis. In many cases the ﬁbroids increase the size
and volume of the uterus and uterine lining with increased
bleeding [5].
2.1. Intermenstrual Bleeding. Submucosal ﬁbroids may also
present with intermenstrual bleeding. This is especially prev-
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ﬁbroids and intermenstrual bleeding must, however, have
a pelvic examination and pap smear to make sure an obvious
cervical cancer is ruled out.
2.2. Haematological Disorders. This is most commonly iron
deﬁciencyanaemiasecondarytouterinehaemorrhage.How-
ever women with ﬁbroids sometimes have polycythemia
[6] due to increased production of erythropoietin and also
thrombocytosis in response to excess bleeding [7]. These two
hematological complications are well known to be associated
with venous thromboembolism and are one mechanism by
which this occurs in patients with ﬁbroids.
2.3. Pressure Eﬀects. These are usually manifest on the uri-
narytract(distortingthebladderproducingurinaryfrequen-
cy or paradoxically acute retention), ureters (causing hy-
drouretersandhydronephrosis),rectum(causingtenesmus),
and veins (principally the left common iliac vein causing
varicosities, venous thromboembolism [8, 9], and leg oede-
ma. These problems are more likely with large ﬁbroids and
renal and venous obstruction are potentially life threatening.
Women diagnosed with these problems need to have the
ﬁbroids removed to prevent permanent kidney damage of
pulmonary embolism.
2.4. Pain. Women with uterine ﬁbroids typically have spas-
modic dysmenorrhoea [10], with the uterus going into
spasms as it tries to expel the large clots and excess blood.
The pain typically starts with the bleeding and ends abruptly
withtheendofthebleeding.Thismustbediﬀerentiatedfrom
congestive dysmenorrhoea which occurs with conditions
suchasendometriosiswherethepainstartsbeforeanybleed-
ing and continues for several days after the end of bleeding.
Many women have both conditions so women who have
clinically palpable ﬁbroids but have congestive-type dysmen-
orrhoea quite often have endometriosis at surgery.
Infarction in ﬁbroids (spontaneous infarction, torsion
causing infarction) can cause quite severe acute pain. Pe-
dunculated subserosal or submucosal ﬁbroids can undergo
torsion. Extrusion of a submucosal ﬁbroid polyp may be as-
sociated with “labour-like” pains.
Fibroids may enlarge to the point that they outgrow their
blood supply and undergo necrosis (red degeneration). This
also causes a great deal of pain for patients. This most com-
monly seen in pregnant women with ﬁbroids and is a com-
mon problem in these women.
2.5. Degeneration in Fibroids. T h e r ea r es e v e r a lt y p e so f
degeneration in a ﬁbroid [11]. Hyaline changes is the com-
monest; it is present in two-thirds of ﬁbroids and consists of
deposition of mucopolysaccharide around the muscle ﬁbres.
Calciﬁcation is also common, especially after the menopause.
These calciﬁcations have been known to result in intestinal
obstruction in postmenopausal women [12]. Fatty changes
are uncommon and usually asymptomatic. Red degeneration
(infarction of ﬁbroid) is commoner in pregnancy.
2.6. Infection. Infection with pyometra may also be asso-
ciated with submucosal ﬁbroids. It is most likely to occur
in the puerperium during uterine involution and when the
cavity is colonized by microorganisms. Pyomyoma is a
rare condition which is seen in pregnant women and
perimenopausal women with vascular disease [8, 9]. In these
women the ﬁbroid becomes necrosed and becomes infected.
The triad of (1) bacteremia or sepsis (2) leiomyoma uteri;
and (3) no other apparent source of infection should suggest
the diagnosis of pyomyoma [13].
2.7.ComplicationinPregnancy. Reddegenerationisthemost
common problem with ﬁbroids in pregnancy and usually
causes severe pain. These women should be treated conser-
vatively as any surgical procedure during the pregnancy can
result in preterm delivery and foetal loss. Although myo-
mectomy in early pregnancy has been successfully done, it
is not recommended because of the risk of maternal hae-
morrhage and foetal loss. Other associated problems include
placenta praevia and intrauterine growth restriction [14],
fetal obstruction with malpresentation or obstructed labour,
postpartum haemorrhage, and puerperal infection. Women
withﬁbroidswhogetpregnantshouldbeallowedtocontinue
pregnancy and all eﬀorts made to make sure they have a
normal haemoglobin at delivery. Delivery should be planned
to ensure the correct route is chosen. Vaginal delivery is
preferred if feasible. Caesarean section is done when needed
and usually a lower segment procedure is better. If small
ﬁbroids are in the lower segment then these can be removed
at the same time. If the lower segment has very large ﬁbroids
then a classical incision may be the better option. Caesarean
myomectomy is a feasible option but with caution. The baby
must be removed before myomectomy is done. If there is
much bleeding during delivery the baby and the placenta,
myomectomymustbepostponed.Anoxytocicagentmustbe
used to prevent haemorrhage at myomectomy, and the use
of vasopressin is a valuable adjunct [15]. Newer drugs such
as carbetocin may be also very valuable here as the oxytocic
eﬀect lasts much longer than oxytocin [16]. In some women
who have very large ﬁbroids and have completed their family
a subtotal hysterectomy at caesarean section may be of value
to avoid an interval procedure.
2.8. Malignant Transformation. One of the most feared com-
plications of ﬁbroids by patients is if the ﬁbroids can become
cancerous.
The answer to this is that this is possible; however, these
eventsareveryrareoccurringinlessthan1%ofpatientswith
ﬁbroids. Patients who have ﬁbroids who have sudden rapid
growth in size or women who notice other symptoms such as
shortness of breath or increased abdominal discomfort need
evaluation. CT scans and MRI can show atypical myomata
and surgery may be recommended. However, the only de-
ﬁnitive way to diagnose leiomyosarcomatous change is by
histological examination.
Other rare histological types have been found such as
intravascular leiomyomatosis and even the more rare intra-
vascular leiomyosarcomatosis ﬁrst described by Coard and
Fletcher [17].
Perimenopausal and postmenopausal women who have
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and have hysterectomy in the event that there is a suspicion
of malignancy.
2.9. Infertility. Several studies have shown that submucous
ﬁbroids are associated with infertility, probably as a result
of decreased implantation [14]. Some studies have also
shown that submucous ﬁbroids are associated with recur-
rent spontaneous abortions. However, in many cases the
infertility preceded the ﬁbroids and the ﬁbroids have grown
because of incessant ovulation. In many of these women the
cause of the infertility is tubal occlusion or endometriosis.
There may also be abnormalities of tubal motility or tubal
obstruction based on the location of the ﬁbroid. Otherwise
ﬁbroid is not a signiﬁcant cause of infertility. Women who
have infertility and ﬁbroids should be properly evaluated
with hysterosalpingograms and laparoscopy. Submucous
ﬁbroids if found should be removed by hysteroscopy [18].
Tubal surgery and myomectomy are notoriously ineﬃcient
in treating infertility as adhesion formation is inevitable.
Fertility after one myomectomy is about 50% and after
t w om y o m e c t o m i e si so n l y1 5 %[ 19]. The use of adhesion
barriers may be beneﬁcial but many of these have not had
the beneﬁt of randomized placebo-controlled trials.
3. Management
Management of a patient with uterine ﬁbroids is highly de-
pendentonthepresentationandpatientwishes.Othercauses
of abnormal bleeding need to be ruled out. In many cases the
management of the ﬁbroids is also risky and in some women
the ﬁbroids are best left alone.
Fibroids are very common and women with small ﬁ-
broids who are asymptomatic are best left untreated. Women
with symptoms who have small ﬁbroids but are close to the
menopause or who are trying to conceive should be treated
conservatively with analgesics and hematinics. Women who
have severesymptoms orvery largeﬁbroids usuallyneed sur-
gical intervention. This may be conservative with myomec-
tomy done by laparotomy (all ﬁbroids), laparoscopy (sub-
serous ﬁbroids), or hysteroscopy (submucous ﬁbroids). All
women going for myomectomy must also be consented for
hysterectomy as haemorrhage is the main complication and
hysterectomy may be life saving when done early enough.
Prior to any treatment women need proper evaluation
with history and examination. This usually will give an idea
oftheseverityofthecondition.Womenmustalsohaveprop-
er laboratory investigation to conﬁrm the severity of their
condition.
A general history must be done to rule out other causes
of bleeding since ﬁbroids are so common. Some women may
in fact be discovered to have a bleeding condition for the
ﬁrst time based on history. They must be asked about social
habits such as excess alcohol intake leading to liver disease.
They should also be asked about other factors suggesting
bleeding diatheses such as bleeding from other oriﬁces and
also presence of purpura and eccymoses.
May women will have other complaints such as pica or
shortness of breath suggesting anaemia. However, if this is
an acute problem remember to rule out pulmonary embo-
lism.
The examination ﬁndings must also be general before
targeting the abdomen. Pallor abdominal swelling and pedal
oedema are common ﬁndings. Unilateral swelling of the legs
is a very suspicious complaint and DVT must be ruled out.
3.1. Laboratory Studies. A complete blood count (CBC) may
be used as a baseline for hemoglobin and hematocrit or to
rule out anemia polycythemia or thrombocytosis. The plate-
let count in conjunction with a peripheral smear may indi-
cate thrombocytopenia, conﬁrming a bleeding disorder in
some cases.
Iron Studies. Total iron-binding capacity (TIBC) ferritin lev-
els are used to assess iron stores when iron deﬁciency is
found. This is not always needed and is done when there is
any doubt about the type of microcytic anemia found.
When bleeding disorders are suspected, studies are used
to rule out von Willebrand’s disease, platelet disorders, and
factor II, V, VII, or IX deﬁciency. These tests should be
ordered sparingly because they are expensive tests for rare
disorders usually done based on level of suspicion from the
history and examination.
Pregnancy remains the most common cause of abnormal
uterine bleeding in patients of reproductive age. Bleeding
usuallydenotesthreatenedabortion,incompleteabortion,or
ectopic pregnancy. A pregnancy test may be of value in cases
where pregnancy is suspected as a possible cause of bleeding
or pain.
Hormonal tests such as follicle stimulating hormone,
luteinizing hormone, progesterone, thyroid function tests
and prolactin level are tests done to rule out conditions that
can cause ovarian dysfunction leading to possible menorrha-
gia.
Liver function and/or renal function tests are done when
liver disease is suspected, such as in persons with alcoholism
or hepatitis. It is very important to rule this out as a cause of
bleeding prior to attempting surgery.
Urea and creatinine tests assess renal function especially
if obstruction has been found on imaging.
3.2. Imaging Studies. Pelvic ultrasound is the best noninva-
sive imaging study to assess uterine shape, size, and contour;
endometrial thickness; adnexal areas. It is also useful to eval-
uate the urinary system. Hydroureters and hydronephrosis
are common ﬁndings in patients with ﬁbroids an indication
that surgical intervention is needed
Sonohysterography (saline-infusion sonography) where
ﬂuid infused into the endometrial cavity enhances intrauter-
ine evaluation. One advantage is the ability to diﬀerentiate
polyps from submucous ﬁbroids.
3.3. Surgical Evaluation. Evaluation of the patient may re-
quire hysteroscopy in some cases and laparoscopy in others.
In one series from Jamaica ﬁbroids were found in 30% of
patientswhohadhysteroscopyforabnormaluterinebleeding
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4. Treatment
4.1. Medical Care. Care should be tailored to the individual.
Factors taken into consideration when selecting the appro-
priate treatment include the patient’s age, coexisting medical
diseases, family history, and desire for fertility. Medication
cost and adverse eﬀects are also considered because they may
play a direct role in patient compliance.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are the
ﬁrst-line medical therapy in ovulatory menorrhagia. These
drugs have been found to be better than placebo in reducing
menstrual blood ﬂow [21].
NSAIDs reduce prostaglandin levels by inhibiting cy-
clooxygenase and increasing the ratio of prostacyclin to
thromboxane. NSAIDs are ingested for only 5 days of the
entire cycle, limiting their most common adverse eﬀect of
stomach upset and the risk of stomach ulceration.
Oral contraceptive pills (OCPs) are a popular ﬁrst-line
therapy for women who desire contraception.
Menstrual blood loss is reduced as eﬀectively as NSAID’s
secondary to endometrial atrophy [22].
OCPs suppress pituitary gonadotropin release, prevent-
ing ovulation. Common adverse eﬀects include breast ten-
derness, breakthrough bleeding, nausea, and, possibly, relat-
ed weight gain in some individuals. Care should be taken in
use of OCPs in women with ﬁbroids as these increase the risk
of venous thromboembolism [23].
Gonadotropin-releasing hormone agonists are used on a
short-term basis due to high costs and severe adverse eﬀects.
T h ea g o n i s t sa r ee ﬀective in reducing menstrual blood ﬂow.
They inhibit pituitary release of FSH and LH, resulting in
hypogonadism. A prolonged hypoestrogenic state leads to
bone demineralization and reduction of high-density lipo-
protein (HDL) cholesterol.
Progestin therapy is the most frequently prescribed med-
icine for menorrhagia. Therapy with progestin results in a
signiﬁcant reduction in menstrual blood ﬂow when used
alone.
Progestin works as an antiestrogen by minimizing the ef-
fects of estrogen on target cells, thereby maintaining the en-
dometrium in a state of downregulation.
Common adverse eﬀects include weight gain, headaches,
edema, and depression.
Levonorgestrel intrauterine system (LIS) reduces men-
strual blood loss by as much as 97% [24]. This is comparable
to transcervical resection of the endometrium for reduction
of menstrual bleeding [25].
The United States FDA approved a new indication for
the levonorgestrel intrauterine system, for the treatment of
menorrhagia in women who use intrauterine conception.
Approval was granted subsequent to a randomized, open-
label, active-control (medroxyprogesterone) clinical trial of
women (n = 160) with established heavy menstrual bleed-




rhea, and breast tenderness.
Depo-medroxyprogesterone acetate (DMPA) which is
inexpensive has been found in our unit to be very valu-
able, reducing menstrual bleeding and allowing women to
improve their haemoglobin prior to surgery [27]. However
like GnRh, DMPA is also antiestrogen and can decrease bone
density when used for a long time [28].
Danazolcompeteswithandrogenandprogesteroneatthe
receptorlevel,causingamenorrheain4–6weeks.Androgenic
eﬀects cause acne, decreasing breast size, and, rarely, lower
voice.
Tranexamic acid was the ﬁrst nonhormonal product
approved by the US FDA (in November of 2009) [29] for the
treatment of heavy menstrual bleeding. Tranexamic acid is a
synthetic derivative of lysine that uses antiﬁbrinolytic eﬀects
by inhibiting the activation of plasminogen to plasmin.
The mechanism of action in treating heavy menstrual
bleeding is by prevention of ﬁbrinolysis and the breakdown
of clots via inhibiting endometrial plasminogen activator.
In a recent, double-blind, placebo-controlled study,
womentaking3.9g/doftranexamicacidshowedasigniﬁcant
reduction in menstrual blood loss and an increase in their
health-related quality of life compared with those taking
placebo[30].Commonadverseeﬀectsincludemenstrualdis-
comfort, headache, and back pain.
4.2. Surgical Care. Surgical management has been the stand-
ard of treatment for ﬁbroids especially when medical therapy
fails to alleviate symptoms. Surgical treatment ranges from a
simple D&C to a full hysterectomy.
4.3. Dilatation and Curettage. A D&C should be used for di-
agnostic purposes. It is best done in women who are peri-
menopausal or any woman found with an excessively thick-
ened endometrium on ultrasonography. It is not used for
treatmentbecauseitprovidesonlyshort-termrelief,typically
1-2 months.
This procedure is used best in conjunction with hys-
teroscopy to evaluate the endometrial cavity for pathology.
It is contraindicated in patients with known or suspected
pelvic infection. Risks include haemorrhage uterine perfora-
tion, infection, and Asherman syndrome.
4.4. Resectoscopic Endometrial Ablation Techniques. Tran-
scervical resection of the endometrium (TCRE) has been
considered the criterion standard cure for menorrhagia for
many years [31]. This procedure requires the use of a re-
sectoscope (i.e., hysteroscope with a heated wire loop), and
it requires time and skill. The primary risk is uterine perfo-
ration.
Roller-ball endometrial ablation essentially is the same as
(TCRE), except that a heated roller ball is used to destroy the
endometrium (instead of the wire loop).
It has the same requirements, risks, and outcome success
as TCRE. Satisfaction rates are also equal to those of TCRE
[32].
Endometrial laser ablation requires Nd:YAG equipment
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The laser is inserted into the uterus through the hyster-
oscope while transmitting energy through the distending
media to warm and eventually coagulate the endometrial tis-
sue.
Disadvantages include the high expense of the equip-
ment, the protracted time required to do the procedure, and
the risk of excessive ﬂuid uptake from the distending media
infusion and irrigating ﬂuid.
Thistechniquehaslargelybeenreplacedbythenonresec-
toscopic systems (discussed below).
Radiofrequency electricity is a detailed microprocessor-
based unit with a bipolar gold mesh electrode array. It con-
tains a system for determining uterine integrity based upon
the injection of CO2.
The device is placed transcervically, the array is opened,
andelectricalenergyisapplied for80to90seconds,desiccat-
ing the endometrium.
Balloon thermohydrotubation is similar to the other
procedures above as the aim is to destroy the endometrial
lining. Heated ﬂuid is instilled into the uterine cavity via
a balloon. This coagulates the endometrium and this invari-
ably stops the menorrhagia. The procedure appears to be
simpler than many of the others mentioned with less side
eﬀect and similar eﬃcacy.
5.SurgicalTechniques
5.1. Myomectomy. Myomectomy can be useful in women
who wish to retain their uterus and/or fertility.
Since myomectomy can be associated with signiﬁcant
blood loss, this procedure is often reserved for cases of a
single or few myomas. In skilled hands many ﬁbroids can be
removed with the use of a hemostatic agent. The procedure
of choice is the use on vasopressin injected perivascularly
around the uterine and ovarian vessels. This occludes both
arms of the anastamosis and hence this has been found to be
superiortooldermethodssuchastourniquetswhichocclude
only the uterine vessels.
The use of vasopressin is relatively new and still evolving.
Thedrugisusuallydilutedto1:19or1:49mlsnormalsaline
if there are many ﬁbroids. Both sides of the broad ligament
are injected to form a bleb around the vessels. Great care
must be taken to avoid intravascular injection as this can
cause systemic vasoconstriction with cardiac ischemia, right-
side cardiac venous return overload, and left-side arterial
constriction with acute hypertension and left hear failure.




ment of as few incisions as possible to avoid tubal occlusion
form direct damage or postoperative adhesions.
The use of postoperative adhesion barriers in this era is
mandatory but this needs further study.
5.2. Hysterectomy. Hysterectomy provides deﬁnitive cure for
ﬁbroids.
This procedure is more expensive and results in greater
morbidity than ablative procedures.
As t u d yb yR o b e r t se ta l .[ 34] reviewed the cost eﬀective-
ness of ﬁrst-generation and second-generation endometrial
ablative techniques, hysterectomy, and the levonorgestrel-
releasing intrauterine system (Mirena) for the treatment of
heavy menstrual bleeding [34]. Although the authors did not
deﬁne “heavy menstrual bleeding,” their analysis concluded
thatthemost cost-eﬀectiveinitial treatmentformenorrhagia
that yielded the best quality of life was hysterectomy.
Other Techniques. Hysterectomy has been found to be safer
than myomectomy as there is less bleeding; however, this
is a deﬁnitive procedure removing any further reproductive
desiresformostwomen.Hysterectomyisalsoassociatedwith
other complications such as bladder or ureteric injury and
also bowel injury. The risk of posthysterectomy vault pro-
lapsed is a well-known entity, and this has resulted in many
gynaecologists especially in Europe doing subtotal hysterec-
tomiesinordertoavoiddamagingthesupportsofthevagina.
Others claim that removal of the cervix is more risky with
more likelihood of damage to the urinary tract. However,
in countries where cancer of the cervix is more common
it is recommended that the cervix be removed since post
hysterectomy cancer of the cervix is more diﬃcult to treat.
Reattaching the cardinal ligaments to the vaginal vault
after total hysterectomy seems to work well in our setting
as vaginal vault prolapsed is not as common in our patients
with this procedure.
5.3. Uterine Artery Embolisation. Uterine artery emboliza-
tion(UAE)isaprocedurewhereaninterventionalradiologist
uses a catheter to deliver small particles that block the blood
supply to the uterine body. The blood supply to the ﬁbroids
is said to be more tenuous than the uterus so the end re-
sultisthattheﬁbroidsbecomenecrosedandshrink.Thepro-
cedure works well in many women who do not want surgery.
However, it can sometimes diminish fertility as the endome-
trium and myometrium can also be necrosed. Its eﬀects on
future fertility need further evaluation in large studies [35].
6. Summary
Uterine ﬁbroids are very common in all ethnicities. They are
especiallyproblematicinwomenofAfro-Caribbeanancestry.
Many women need no intervention for their ﬁbroids. Many
women only need conservative treatment. This can be med-
ical treatment or surgical. The management of uterine ﬁ-
broids requires the balance of the complications of the ﬁ-
broids versus the risks of the treatment options.
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